Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Practice Point
  • Published:

How effective is eltrombopag for the treatment of thrombocytopenia in patients with HCV infection?

Nature Clinical Practice Gastroenterology & Hepatology volume 5, pages 424–425 (2008)Cite this article

boxed-textMcHutchison JG et al. (2007) Eltrombopag for thrombocytopenia in patients with cirrhosis associated with hepatitis C. N Engl J Med 357: 2227–2236

Thrombopoietic agents will enable many more patients infected with HCV who have thrombocytopenia to initiate and successfully complete a potentially curative course of antiviral treatment

This is a preview of subscription content, access via your institution

Access options

Buy this article

  • Purchase on Springer Link
  • Instant access to full article PDF
Buy now

Prices may be subject to local taxes which are calculated during checkout

References

  1. McHutchison JG et al. (2002) International hepatitis interventional therapy, adherence to combination therapy enhances sustained response in genotype-1-infected patients with chronic hepatitis C. Gastroenterology 123: 1061–1069

    Article  CAS  Google Scholar 

  2. Kaushansky K (2005) The molecular mechanisms that control thrombopoiesis. J Clin Invest 115: 3339–3347

    Article  CAS  Google Scholar 

  3. Bussel JB et al. (2007) Eltrombopag, an oral platelet growth factor, for the treatment of patients with chronic idiopathic thrombocytopenic purpura. N Engl J Med 357: 2237–2247

    Article  CAS  Google Scholar 

  4. Bussel JB et al. (2006) Effect of a novel thrombopoiesis-stimulating protein (AMG 531) in chronic immune thrombocytopenic purpura. N Engl J Med 355: 1672–1681

    Article  CAS  Google Scholar 

  5. Kuter DJ et al. (2008) Efficacy of romiplostim in patients with chronic immune thrombocytopenic purpura: a double-blind randomized controlled trial. Lancet 371: 395–40

    Article  CAS  Google Scholar 

Download references

Acknowledgements

The synopsis was written by Rachel Jones, Associate Editor, Nature Clinical Practice.

Author information

Authors and Affiliations

  1. JB Bussel is a Professor of Pediatrics and KM Marks is an Assistant Professor of Medicine at Weill Cornell Medical College, New York, NY, USA.,

    James B Bussel & Kristen M Marks

Authors
  1. James B Bussel
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Kristen M Marks
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to James B Bussel.

Ethics declarations

Competing interests

The authors declare no competing financial interests.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Bussel, J., Marks, K. How effective is eltrombopag for the treatment of thrombocytopenia in patients with HCV infection?. Nat Rev Gastroenterol Hepatol 5, 424–425 (2008). https://doi.org/10.1038/ncpgasthep1185

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/ncpgasthep1185

Search

Advanced search

Quick links

Nature Briefing

Sign up for the Nature Briefing newsletter — what matters in science, free to your inbox daily.

Get the most important science stories of the day, free in your inbox. Sign up for Nature Briefing